Association between experience of specific side-effects and contraceptive switching and discontinuation in Uganda: results from a longitudinal study

Linnea A. Zimmerman1,* Dana O. Sarnak1, Celia Karp1, Shannon N. Wood1, Saifuddin Ahmed1, Fredrick Makumbi2 and Simon P. S. Kibira3

Abstract

Background: There is substantial evidence that contraceptive side-effects are a major deterrent to consistent use of contraception but few studies in low- or middle-income countries explore the role of specific side-effects on contraceptive use dynamics. This study used population-based, longitudinal data to explore the effect of specific side-effects on contraceptive continuation, discontinuation, and switching in Uganda.

Methods: Data for this study come from two rounds of survey data collection in Uganda: PMA2020’s sixth cross-sectional survey and a follow-up survey conducted 1 year later. The main outcomes of interest were discontinuation and switching among users of hormonal contraceptive methods (implants, injectables and oral pill) and the IUD at baseline ($n = 560$). Multivariable logistic regressions assessed the association of experiencing specific side-effects (more bleeding, less bleeding, irregular bleeding, increased dryness/reduced libido, and physical discomfort) with discontinuation and switching 1 year later, adjusting for socio-demographic characteristics, type of method, and length of use. We also examined the differential effects of side-effects between discontinuation and switching risks.

Results: About 23% of hormonal and IUD contraceptive users reported experiencing side-effects at baseline survey. Overall, discontinuation and switching were higher among injectables and pill users, compared to IUD and implants users. Reporting more bleeding or less bleeding increased the odds of discontinuation and switching by 2.74 (95% CI 1.00–7.51) and 1.86 (1.04–3.34), respectively. There was no significant difference in discontinuation and switching by side-effects.

Conclusions: Greater attention should be paid to understanding the unique contributions of side-effects to contraceptive behavior using population-based data. While about a quarter of women reported experiencing side effects, those who experienced bleeding specific side effects were at higher risk of contraceptive discontinuation and switching. Providing greater individualized care that includes information and counseling about common side-effects, how they may impact daily life, and how tolerable these effects may be is necessary.

Keywords: Contraceptive side-effects, Contraceptive continuation, Contraceptive switching, Longitudinal, Menstrual bleeding, Sexual experience, Uganda
Background
There is substantial evidence that contraceptive side-effects, either experienced or perceived, are a major deterrent to consistent use of contraception [1–4]. Across diverse settings, women report experiencing changes to menstrual bleeding, abdominal pain, weight gain, changes to sexual experience, and non-specific “weakness” as influencing their decision-making about contraception [5–12]. Though providing critical contextual data, qualitative data are unable to assess how widespread experiences are, how these experiences contribute to contraceptive use dynamics at a population level, and what side-effects may be largely tolerated by women versus those that lead to discontinuation or switching.

Population-based national surveys with publicly available data on family planning, such as the Demographic and Health Survey (DHS), Performance Monitoring and Accountability (PMA2020, now Performance Monitoring for Action (PMA)) and the Multiple Indicator Cluster Survey (MICS), do not include questions that identify specific side-effects, instead identifying only generalized “side-effects” or “health concerns” as a reason for contraceptive discontinuation [8, 13, 14]. Recent efforts have called for increased specificity of side effect data. Specifically, one review indicates that while changes to menstrual bleeding, including increased bleeding, amenorrhea, and irregular bleeding and spotting, have been shown to be particularly influential on contraceptive use, there is a lack of nationally representative data available on the experience of these side-effects [15]. Another recent review of contraceptive-induced changes to sexual experience similarly noted both the importance that is placed on these changes by women and the critical dearth of research within low- and middle-income countries (LMICs) [16]. Similar knowledge gaps exist around the prevalence and consequences of additional side-effects, such as nausea and headaches [5, 12, 17]. This lack of knowledge limits our understanding of both the prevalence and effects of specific contraceptive induced side-effects on contraceptive behaviors.

Beyond understanding the prevalence of side-effects in a population, it is also important to understand what factors may influence the tolerability of side-effects; that is, what factors are associated with women continuing to use a method in the presence of side-effects. This question is particularly relevant to consider in the context of LMICs, as the vast majority of research has been limited to high-income settings or conducted as part of clinical trials [18–23]. Tolerability of specific side-effects may differ for a variety of social, cultural, and economic reasons; how side-effects are interpreted, treated (e.g. availability and accessibility to menstrual hygiene products or treatment for cramping), and the economic and physical consequences when they are experienced are heavily influenced by context and quality of available services [6, 10, 24–26]. Findings from high-income countries should not, therefore, be applied to LMIC contexts nor should findings from one LMIC be roteapplied to another. Gaining a more nuanced understanding of the characteristics of women in specific settings who tolerate side-effects and continue using contraception, versus those that discontinue, may thus provide valuable lessons to program managers and health providers.

Finally, limited research has explored how the experience of specific side-effects may motivate switching to a different method versus discontinuing contraception altogether. Contraceptive switching has significant programmatic implications for (1) promoting the use of more-effective, long-acting methods from lesser effective methods; (2) addressing discontinuation related to
experienced side-effects by promoting alternative contraceptive methods; (3) ensuring that women are able to choose a method that best aligns with their reproductive goals—a critical component of high-quality, rights-based family planning programs [27–30]. While the outcome of switching is generally considered positive due to sustained protection against unintended pregnancy, there is significantly less known about what motivates switching versus discontinuation and what facilitates or impedes this decision. To our knowledge, the only prospective study in LMICs to assess specific side-effects and their effect on contraceptive switching versus discontinuation was conducted by Barden-O’Fallon and colleagues among women in Honduras [31]. The authors found that Honduran women who experienced amenorrhea or heavy menstrual bleeding were significantly more likely to discontinue than switch methods and that urban women were significantly more likely to switch methods than rural women, underscoring the simultaneous roles of side-effects and sociodemographic characteristics on women’s contraceptive practices. However, the study did not compare switching and discontinuing separately to assess the effect of experiencing side-effects on these behaviors, relative to continuation. Despite the logical contribution of side-effects to women’s decisions to adopt a different method or stop using contraception entirely, there is a clear dearth of research in this area.

To better understand the prevalence of different side-effects and their association with contraceptive use dynamics, a longitudinal study was conducted in Uganda. This study aimed to estimate the prevalence of a range of specific side-effects that were experienced among users of hormonal contraception and the IUD and to establish the association between these side-effects and contraceptive discontinuation, switching, or continuation 1 year later. Additionally, we sought to identify relevant socio-demographic characteristics associated with discontinuation and with switching.

Methods

Study setting

Uganda had a population of about 44.3 million in 2019, with nearly half its population under age 15 [32]. Uganda is characterized by high fertility; the total fertility rate (TFR) in 2016 was 5.4 births, down from 6.9 in 2000–2001 [13]. Modern contraceptive use in Uganda has also increased in recent years, from 21% in 2014 to 30% in 2018. Injectables were the most common method used in 2018 (39%), followed by implants (20%) (ibid). Despite the increase in contraceptive use, high rates of contraceptive discontinuation persist; nationally, 20% of IUD users, 17% of implant users, 36% of injectable users, and 46% of pill users discontinued in the 1st year of use, while in need of protection against unintended pregnancy (ibid).

Study overview and sampling

Data for this study come from two rounds of PMA2020 data collection in Uganda. Specifically, in PMA2020 Uganda’s sixth cross-sectional survey [14], conducted from April to June 2018 (hereafter referred to as baseline), the consent and design were modified to enroll women in a longitudinal study. A follow-up survey was conducted approximately after 1-year from May to June 2019.

PMA2020 is a multi-stage cluster, nationally representative survey of women age 15–49. In the baseline survey, 110 Enumeration Areas (EA) were selected using probability proportional to size sampling and all occupied households were enumerated. Forty-four households were randomly selected within each EA, consented, and interviewed. All women age 15–49 who were either usual members of the household or who slept in the household the night before were approached for interview, and if consented, interviewed by a trained interviewer. A total sample of 4288 women were interviewed in the baseline survey (response rate: 96.9%); the majority (95.5%; n = 4095) of women agreed to participate in the follow-up survey. Further information on the design of PMA2020 surveys is available from www.pmadata.org and Zimmerman et al. [33].

At follow-up, interviewers returned to the households of women who completed the baseline survey and re-consented women to participate in the follow-up survey. We were able to relocate and successfully interview 2755 women from the original sample, resulting in a follow-up rate of 67%. Due to potential bias from loss to follow-up, we constructed an inverse probability weight from estimated propensity scores to adjust for differential loss to follow-up. Using the total sample of women from baseline (n = 4288), we adjusted for the probability of being interviewed at follow-up accounting for age (5-year age groups), education (none, primary, secondary and higher), marital status (currently married/in-union, not married), wealth (five quintiles), and residence (urban,rural). The original baseline individual female weight was then multiplied by the inverse probability weight to construct the final weight in the analyses. We assessed differences between women who were in the analytic sample (outlined further below)
and followed-up (n = 560) versus those that met the criteria for the analytic sample but were lost to follow-up (n = 233). Overall, women who were lost-to-follow-up were younger, less likely to be married, more likely to live in an urban area and be of low parity, less likely to say they did not want to have any more children, and more likely to have used their method fewer than 12 months. Overall, their contraceptive related outcomes (method choice and experience of side-effects) were similar to the study sample (shown in Appendix Table 6).

Analytic sample
This analysis was restricted to women who reported currently using hormonal contraception (implant, injectable, pill) or the IUD at baseline. Of note, we are unable to differentiate between hormonal and non-hormonal IUD use. Users of emergency contraception were excluded due to the periodicity in its use, and female sterilization users were excluded as they would not be able to discontinue or switch methods. Condoms and other barrier and traditional methods were excluded as systemic side-effects were not anticipated from using these methods. Women who wanted to have another child within 1 year at baseline were excluded (n = 76) as they may have discontinued to become pregnant irrespective of their side-effects experience. In total, 560 women were included in this analysis; the flowchart of sample selection process is shown in Fig. 1. Data were complete for all observations used in analysis. The follow-up rate for the analytic sample was 71%; 560 users were relocated out of 793 pill, implant, injectable, and IUD users at baseline who did not want to become pregnant in the next year.

Measures
At baseline, women were asked to report whether they were currently experiencing any side-effects, and if so, to specify all that they were currently experiencing (with multiple-response options; responses were not prompted or read aloud). The list of side-effects was drawn from the literature on clinically documented side-effects, and those that have been reported in qualitative research in Uganda. The list was reviewed with the in-country team and pilot tested; the complete list of side-effects is shown in Appendix Table 7. Women were coded as 1 if they reported experiencing each side-effect and 0 if not.

The outcomes related to contraceptive behavior were defined based on the woman’s contraceptive use status at the time of follow-up survey. Specifically, women were categorized in to three groups: either continued (using the same method at baseline and follow-up), switched (using a different method at baseline and follow-up), or discontinued (not using a method at follow-up). First, we examined the odds of method-specific discontinuation, which included discontinuation and switching, compared to continuation, and then we examined discontinuation compared to switching by side-effects reporting. We assessed the distribution of each outcome by method type (implant, IUD, injectables, and oral pills).

Covariates
All analyses were adjusted for the following socio-demographic variables measured at baseline: age (included as a continuous variable), marital status (binary variable indicating married/in-union), residence (urban or rural), education (categorical variable indicating none, primary, or secondary and above), and parity (categorical variable of 0–1, 2–3, or 4+ children). We combined nulliparous
and primiparous women, as there were only nine nulliparous women included in the analytic sample. Due to low-prevalence of side-effects and sample size limitations, we created a binary variable for wealth, indicating whether the respondent resided in a household in one of the lowest two wealth quintiles (0) or the wealthier three (1). We adjusted for method used at baseline by including a categorical variable of method type. To account for the fact that side-effects may be more frequent when initiating a method and resolve over time, we included a binary variable indicating whether the woman started her method less than 12 months prior to the baseline interview. We used a 12-month time frame to align with previous research [31]. Finally, we adjusted for stated fertility intentions at baseline (wanted child within 2 years, wanted child after 2 years, wanted no more children).

Analysis
Exploratory analyses assessed the prevalence of each side-effect for further modeling considerations. Based on sample size, the following side-effects were combined: “uterine cramping”, “cramping”, “headache”, “nausea”, and “weakness” (“physical discomfort”); “vaginal dryness” and “lowered libido” (“vaginal dryness/lowered libido”); “spotting” and “irregular bleeding” (“irregular bleeding”).

We fit two multivariable logistic regression models: first, we assessed the risk of discontinuing or switching, relative to continuing, among women who reported experiencing the side-effect compared to women who did not, and then examined the risk of discontinuation compared to switching after excluding the women who continued. As women could experience multiple side-effects simultaneously, we ran adjusted models that included all side-effects and the covariates listed above. Sensitivity analyses were conducted with the inclusion of each side-effect independently and results were largely consistent (results not shown).

Descriptive analyses (Tables 1, 2 and 3) applied the survey weights described above. Due to small sample sizes and because weighting increases variances and design-effects substantially, we tested the efficiency of the application of weights in the logistic regressions and to maximize efficiency, we followed guidance from Korn and Graubard and did not apply the survey weights to the regression models [34]; we did, however, adjust variances for clustering-effects using design-based regression with Taylor linearization method. All analyses were conducted using Stata v16.0 [35]. We followed the STROBE cohort checklist when writing our paper [36].

Results
The characteristics of women in the analytic sample are shown in Table 1. The mean age of women in the sample was approximately 30 years old. The majority of women

| Table 1 | Sample characteristics of current hormonal contraceptive or IUD users at baseline, weighted (n = 560) |
|---------|-----------------------------------------------------------------------------------|
| Variables | Followed-up sample |
| N = 560 | |
| | % | 95% CI |
| | LL | UL |
| Age | | |
| Mean (in years) | 30.3 | 29.5 | 31.2 |
| Married or in-union | 86.8 | 82.1 | 90.4 |
| Urban | 16.7 | 10.1 | 26.2 |
| Parity | | |
| 0–1 | 13.9 | 10.1 | 18.0 |
| 2–3 | 32.0 | 23.1 | 42.5 |
| 4+ | 52.7 | 45.6 | 59.8 |
| Education | | |
| None | 7.2 | 4.6 | 11.0 |
| Primary | 57.2 | 50.5 | 63.5 |
| Secondary+ | 35.7 | 29.1 | 42.8 |
| Wealth | | |
| Lowest 40% | 34.7 | 28.2 | 41.8 |
| Highest 60% | 65.3 | 58.3 | 71.7 |
| Fertility desires | | |
| Want in 1–2 years | 12.2 | 9.1 | 16.2 |
| Want in 2+ years | 42.6 | 36.8 | 48.6 |
| Do not want anymore | 45.2 | 39.5 | 51.1 |
| Using < 12 months | 51.4 | 45.8 | 56.9 |
| Method | | |
| Implant | 31.9 | 26.8 | 37.4 |
| IUD | 4.6 | 2.7 | 7.6 |
| Injectable | 56.8 | 50.6 | 62.8 |
| Pill | 6.8 | 4.6 | 9.8 |
| Number of side effects | | |
| None | 77.2 | 72.1 | 81.7 |
| 1 | 48.3 | 30.0 | 75.0 |
| 2 or more | 18.0 | 13.8 | 23.0 |
| Specific side effect | | |
| Less bleeding | 9.3 | 6.2 | 13.6 |
| More bleeding | 5.6 | 3.5 | 9.0 |
| Irregular bleeding | 7.3 | 4.4 | 11.9 |
| Changes to sexual experience | 5.4 | 3.1 | 9.2 |
| Physical discomfort | 13.1 | 9.2 | 18.4 |
(86.8%) were married or in-union. Less than 15% of contraceptive women at baseline were nulliparous or primiparous and the vast majority (approximately 93%) had attended at least some schooling, with the majority attending only primary school (57.2%). Two in three women included in the analytic sample resided in wealthier households. The majority of women wanted to either wait more than two years to their next birth (42.6%) or have no more children (45.2%). About half of women reported that they had been using the current contraceptive method for fewer than 12 months. The majority of women were using the injectable (56.8%) followed by the implant (31.9%).

Approximately one in four of women reported experiencing any side-effects at baseline, while 4.8% were experiencing one side-effect and 18.0% reported experiencing two or more. Physical discomfort was the most commonly reported side-effect reported (13.1%), followed by less bleeding (9.3%).

Table 2 shows the percentage of women who continued the same method at follow-up interview, switched, or discontinued by method type. In total, 47.8% of users were using the same method at follow-up; 20.3% had switched methods; and 31.9% had discontinued use. Switching was highest among pill users, while discontinuation was highest among injectable users.

Table 3 shows the percentage of women who discontinued, switched, and continued by side-effect reported at baseline. Discontinuation was highest among women who reported irregular bleeding (48.9%) and switching was highest among women who reported bleeding more (22.8%) or experiencing changes to sexual experience (22.4%). Continuation was highest among women who reported no side effects.

The adjusted odds ratios for discontinuation and switching relative to continuation are shown in Table 4. Reporting less or more bleeding at baseline increased the odds of discontinuation or switching by 1.86 times (95% CI 1.04–3.34) and 2.74 (95% CI 1.04–7.78) times, respectively. When included in the model alone, irregular bleeding increased the odds of discontinuation and switching by 2.04 times (data not shown: unadjusted OR: 2.04; 95% CI 1.05–3.96, p-value = 0.035), but was not statistically significant in the adjusted model (adjusted OR: 1.31; 95% CI 0.58–2.91). Reporting vaginal dryness/lowered libido and physical discomfort were not associated with discontinuation and switching. Women who used their method for fewer than 12 months had 1.47 times higher odds of discontinuing or switching (OR: 1.47; 95% CI 1.02–2.11), while users of injectables and pills had significantly higher odds of discontinuing or switching than implant users.

Wealth was significantly associated with discontinuation; women who lived in the wealthiest 60% of households had 35% lower odds of discontinuing or switching, relative to continuing (OR: 0.65; 95% CI 0.44–0.96).

Table 2  Contraceptive discontinuation, switching, and continuation by method used at baseline, row percentage (weighted)

| Method          | Discontinued | Switched | Continued | Total | Total |
|-----------------|--------------|----------|-----------|-------|-------|
| Implants        | 26.0         | 12.7     | 61.2      | 100.0 | 187   |
| IUD             | 15.9         | 19.4     | 64.7      | 100.0 | 28    |
| Injectables     | 36.4         | 24.1     | 39.5      | 100.0 | 300   |
| Pill            | 32.9         | 24.4     | 42.7      | 100.0 | 45    |
| Total           | 30.4         | 20.6     | 49.0      | 100.0 | 560   |

Table 3  Discontinuation, switching, and continuation by side-effect reported at baseline among current users of hormonal contraception or IUD, row percentage (weighted)

| Side-effect                  | Discontinued | Switched | Continued | N   |
|------------------------------|--------------|----------|-----------|-----|
| Any side-effect              | 38.3         | 23.3     | 38.4      | 121 |
| No side-effects              | 30.1         | 19.4     | 50.6      | 439 |
| Menstrual changes            |              |          |           |     |
| Less bleeding                | 31.8         | 19.6     | 31.2      | 47  |
| More bleeding                | 41.4         | 22.8     | 35.8      | 30  |
| Irregular bleeding           | 48.9         | 17.3     | 33.9      | 37  |
| Other bodily changes         |              |          |           |     |
| Changes to sexual experience | 36.6         | 22.4     | 41.1      | 26  |
| Physical discomfort          | 32.3         | 20.6     | 44.0      | 70  |

Women could report multiple side-effects (multiple-response)
Women using the method for less than 12 months at baseline had approximately 50% higher odds of discontinuation and switching (OR: 1.47; 95% CI 1.02–2.11). Women who wanted another child in more than 2 years or who did not want another child were significantly less likely to discontinue or switch methods than women who wanted another in 1–2 years [(OR: 0.45; 95% CI 0.25–0.79) and (OR: 0.35; 95% CI 0.18–0.70), respectively].

Table 5 shows the odds ratios of discontinuation relative to switching after adjusting for relevant background characteristics (n = 292).

| Variables                          | Odds ratio (OR) | 95% conf. interval | p-value |
|------------------------------------|-----------------|--------------------|---------|
| N                                 |                 |                    |         |
| Bleeding less                      | 1.86            | 1.04 3.34          | 0.037   |
| Bleeding more                      | 2.74            | 1.00 7.51          | 0.050   |
| Bleeding irregularly               | 1.31            | 0.58 2.91          | 0.512   |
| Change in sexual experience        | 0.95            | 0.40 2.25          | 0.913   |
| Physical discomfort                | 1.24            | 0.69 2.24          | 0.470   |
| Using the method < 12 months       | 1.47            | 1.02 2.11          | 0.040   |
| Method (ref: Implant)              |                 |                    |         |
| IUD                                | 0.85            | 0.33 2.17          | 0.730   |
| Injectables                        | 2.18            | 1.47 3.23          | < 0.001 |
| Pill                               | 3.32            | 1.68 6.56          | 0.001   |
| Age                                | 1.02            | 0.98 1.06          | 0.261   |
| Parity (ref: 0–1)                  |                 |                    |         |
| 2–3                                | 0.96            | 0.56 1.64          | 0.874   |
| 4+                                 | 0.90            | 0.45 1.80          | 0.760   |
| Married or in union (ref: Not married) | 0.67 | 0.41 1.09 | 0.103 |
| Urban (ref: Rural)                 | 1.34            | 0.80 2.24          | 0.261   |
| Education (ref: None)              |                 |                    |         |
| Primary                            | 1.01            | 0.52 1.97          | 0.976   |
| Higher                             | 1.10            | 0.51 2.34          | 0.811   |
| Wealth (ref: lowest 40%)           | 0.65            | 0.44 0.96          | 0.030   |
| Fertility desire (ref: Want 1–2 years) | 0.45 | 0.25 0.79 | 0.006 |
| Want in 2+ years                   | 0.45            | 0.25 0.79          | 0.006   |
| Do not want anymore                | 0.35            | 0.18 0.70          | 0.003   |

**Discussion**

We found that approximately one-quarter of women using a hormonal method or the IUD reported currently experiencing at least one side-effect, and that the associations between the experience of side-effects and switching or discontinuation varied substantially based on the nature of the side-effect. Experiencing more or less bleeding increased method specific discontinuation. None of the side-effects examined affected whether women switched versus discontinued, however. These results underscore the importance of examining the unique influence of specific side-effects, instead of the broad singular category of “side-effects and health concerns.” Failure to investigate specific contraceptive side-effects
inhibits understanding of nuanced relationships between women’s experiences, their adaptive responses, and subsequent contraceptive behaviors.

Our finding that increased menstrual bleeding was associated with discontinuation aligns with a growing body of literature, highlighting the importance of contraceptive-induced bleeding changes [1, 15, 17]. Excessive bleeding arose as a major barrier to contraceptive use in previous qualitative research in Uganda [12, 37, 38]. One explanation may be that experience of excessive bleeding may present practical challenges to menstrual hygiene management. While limited, research in Uganda has highlighted a range of barriers to effective menstrual hygiene management, resulting from resource limitations and sociocultural norms [39–42]. Despite the conceptual link between contraceptive-induced bleeding changes and menstrual hygiene management, there is extremely limited research available on this subject, and the majority of studies focus on the experience of adolescent girls [42]. Experience of changes in menstrual bleeding may be additionally problematic in environments like Uganda, where myths and misperceptions around the harmful impacts of contraception, including effects on future fertility and on overall health, are widespread [12, 43, 44]. In high-fertility countries such as Uganda, where childbearing is highly valued, changes to menstrual bleeding may not be viewed simply as an inconvenience, but as a prequel to infertility [6, 12]. This belief carries profound social consequences and, therefore, may greatly reduce motivation to use contraception [6, 45].

Evidence from qualitative studies in Africa suggests that amenorrhea and irregular bleeding are often viewed negatively and associated with concerns about future fertility, particularly among nulliparous women [15]. We find that bleeding less increased discontinuation and switching. Similarly, irregular bleeding increased the odds of discontinuation and switching, but was not statistically significant once we accounted for more or less bleeding. Changes to bleeding patterns may affect women’s ability to participate in daily activities, such as religious and work events [10], and the ability to accommodate irregular bleeding is likely to vary across social groups or according to beliefs about potential consequences of such side-effects. Of note, we did not distinguish between less bleeding and cessation of bleeding. Future research should attempt to distinguish between these two bleeding patterns, as complete cessation may engender different behavioral responses than a lighter, but consistent, menstrual period.

We find that vaginal dryness/ lowered libido and physical discomfort were not related to an increased odds of discontinuation or switching. Very little research has explored either quantitatively or qualitatively how changes to sexual experience induced by contraceptive use affect contraceptive dynamics, despite evidence that this is an important consideration for both the woman and her partner [10, 12, 16, 46]. Similarly, physical discomfort, which here included headache, nausea, weakness, and cramping, have generally not been included in studies that assess the impact of side-effects. A recent study by Odwe and colleagues found that 30–50% of current and recent injectable and implant users experienced some form of non-bleeding side-effects, often in conjunction with bleeding changes, and that satisfaction with their method was associated with the experience of both bleeding and non-bleeding side-effects [17]. Barden-O’Fallon and colleagues found that abdominal cramping was not associated with the decision to switch versus stop method use. However, the authors did not assess whether cramping increased the overall risk of either relative to continuation [31]. This limits our ability to compare our findings to other studies and underscores the critical need to explore these areas of contraceptive use and experience more fully. We also note that we did not assess severity or frequency of side-effects; women who experience more severe side-effects or more frequent side-effects may discontinue at higher rates than others as Jain and colleagues found in India, adding further nuance to understanding the effect of side-effects on contraceptive behavior [26].

A secondary objective of this paper was to gain a better understanding of the characteristics of women who continue, discontinue, and switch methods after experiencing side-effects, in order to explore how life circumstances influence contraceptive decision-making. Due to sample size limitations, we could not limit our analyses to only women who reported experiencing a side-effect, however, we were able to identify several relevant socio-demographic characteristics associated with discontinuation and switching, after adjusting for the experience of specific side-effects. Wealth was associated with decreased relative risk of discontinuation and switching relative to continuation, while education was associated with an increased risk of switching relative to discontinuation, indicating that social privilege may influence contraceptive dynamics in different ways. For example, social disadvantages that inhibit poorer women from accessing healthcare services to adopt new methods may result in
higher discontinuation among this population. Educated women may be more knowledgeable about a range of contraceptive methods than less educated women, allowing them greater opportunity to switch methods if they are dissatisfied. More research on what influences women to discontinue versus switch contraceptive methods after experiencing side-effects is necessary so that family planning programs can better tailor services.

A potential limitation of our study is that women were asked to spontaneously report side-effects that they were currently experiencing, rather than replying directly to a list of potential side-effects. To do so, women needed to consider what they were experiencing as a side-effect of their contraceptive method and, in the case of amenorrhea and loss of libido, recognize the absence or reduction of these experiences as being currently experienced. It is possible that women are less likely to report something that is not happening as being “currently experienced,” relative to something that has increased or newly presented, but this requires further investigation. Additionally, women may not report currently experiencing more bleeding if they are not menstruating. Reading a list of potential side-effects and requiring a response may be a more effective way to gather information on prevalence of side-effects, but may also result in over-reporting [47, 48]. This calls for further methodological research to identify how best to accurately identify and quantify the experience of side-effects in large-scale, population-based surveys.

Under-reporting, in addition to our lower than expected retention, may have contributed to our limited analytical sample size. The limited absolute numbers of women, particularly for switching, restricted our ability to explore relationships across the full range of side-effects. Additionally, our retention at study level was 67%. The application of propensity scores to adjust for loss-to-follow-up allowed us to construct weights that generated estimates of sample characteristics that did not differ between the full baseline and the sample of women who successfully completed follow-up. While we believe we thus adjusted for the majority of demographic and economic characteristics that may be related to contraceptive continuation, there were differences between women who were lost-to-follow-up and those who were included in our sample. Women who were included were older, had higher parity, and were more likely to say they wanted no more children. These women may thus have stronger preferences to prevent childbearing and be more motivated to use contraception [49] despite experiencing side-effects, resulting in conservative estimates of the effect of side-effects; however, as noted, there is little research on tolerability to which we can effectively compare. Finally, we defined switching and discontinuation only based on baseline and follow-up and were unable to account for events that occurred between the two time points, including both the onset of side-effects and switching or discontinuation in the interim. Though we included a contraceptive calendar for this purpose, we found that recall of starting and ending dates of methods when reported retrospectively was inconsistent and rendered the calendar data unusable for this purpose. As we were unable to account for the month-by-month changes between the two surveys, we could have missed behaviors (additional discontinuation/switching of methods) that occurred between the two time points. We believe that this means our estimates are likely conservative, i.e. that we are under-estimating discontinuation and switching and over-estimating continuation.

Despite these limitations, our study has several important strengths. First, we were able to identify and assess the effects of a range of side-effects, including some which have not been extensively studied in the literature. Additionally, we used longitudinal data, following up with women 1 year after the baseline survey, enabling us to assess how these specific side-effects related to discontinuation and switching independently, providing additional insight into contraceptive behaviors.

Conclusion
Women do not experience generalized “side-effects and health concerns”; they experience specific side-effects and contraceptive behavior is influenced based on both the side-effect and on the woman’s unique circumstances and context. Identifying which side-effects are commonly experienced and strongly associated with discontinuation and switching, in addition to identifying some of the socio-demographic characteristics that may be associated with these behaviors, has valuable programmatic purposes. Counseling that incorporates discussions about individualized suitability for specific side-effects and more discussion about the possibility of switching methods when side-effects do occur may improve continuation rates. Additional research should explore in greater detail the role that context, including partner support, plays in the decision to stop or switch methods.
Appendix
See (Tables 6 and 7).

Table 6 Sociodemographic characteristics of hormonal contraceptive and IUD users by follow-up status

| Variables                  | Followed-up sample | Lost-to-follow-up sample |
|----------------------------|--------------------|--------------------------|
|                            | N = 560            | N = 233                  |
|                            | %                  | %                        |
|                            | 95% CI             | 95% CI                   |
|                            | LL                | UL                       |
|                            | LL                | UL                       |
| Age                        |                    |                          |
| 15–24                      | 27.0              | 41.6                     |
|                            | 22.3              | 33.1                     |
|                            | 32.4              | 50.7                     |
| 25–34                      | 43.7              | 39.5                     |
|                            | 38.8              | 30.7                     |
|                            | 48.7              | 49.1                     |
| 35+                        | 29.3              | 18.8                     |
|                            | 25.1              | 13.3                     |
|                            | 33.9              | 25.9                     |
| Mean (in years)            | 30.3              | 27.2                     |
|                            | 29.5              | 26.1                     |
|                            | 31.2              | 28.3                     |
| Married or in-union        | 86.8              | 73.2                     |
|                            | 82.1              | 62.9                     |
|                            | 90.4              | 81.4                     |
| Urban                      | 16.7              | 27.3                     |
|                            | 10.1              | 17.1                     |
|                            | 26.2              | 40.7                     |
| Parity                     |                    |                          |
| 0–1                        | 13.9              | 32.0                     |
|                            | 10.1              | 23.1                     |
|                            | 18.0              | 42.4                     |
| 2–3                        | 33.4              | 33.6                     |
|                            | 27.8              | 25.8                     |
|                            | 39.4              | 42.3                     |
| 4+                         | 52.7              | 34.4                     |
|                            | 45.6              | 25.8                     |
|                            | 59.8              | 44.2                     |
| Education                  |                    |                          |
| None                       | 7.2               | 8.5                      |
|                            | 4.6               | 4.6                      |
|                            | 11.0              | 15.2                     |
| Primary                    | 57.2              | 56.8                     |
|                            | 50.5              | 46.2                     |
|                            | 63.5              | 66.8                     |
| Secondary+                 | 35.7              | 34.7                     |
|                            | 29.1              | 24.7                     |
|                            | 42.8              | 46.3                     |
| Wealth                     |                    |                          |
| Lowest 40%                 | 34.7              | 32.1                     |
|                            | 28.2              | 23.8                     |
|                            | 41.8              | 41.6                     |
| Highest 60%                | 65.3              | 67.9                     |
|                            | 58.3              | 58.4                     |
|                            | 71.7              | 76.2                     |
| Fertility desires          |                    |                          |
| Want in 1–2 years          | 12.2              | 17.3                     |
|                            | 9.1               | 12.1                     |
|                            | 16.2              | 24.1                     |
| Want in 2+ years           | 42.6              | 50.7                     |
|                            | 36.8              | 42.8                     |
|                            | 48.6              | 58.5                     |
| Do not want anymore        | 45.2              | 32.0                     |
|                            | 39.5              | 24.8                     |
|                            | 51.1              | 40.2                     |
| Using < 12 months          | 51.4              | 63.2                     |
|                            | 45.8              | 55.2                     |
|                            | 56.9              | 70.6                     |
| Method                     |                    |                          |
| Implant                    | 31.9              | 35.3                     |
|                            | 26.8              | 26.8                     |
|                            | 37.4              | 44.7                     |
| IUD                        | 4.6               | 2.5                      |
|                            | 2.7               | 1.1                      |
|                            | 7.6               | 5.6                      |
| Injectable                 | 56.8              | 53.2                     |
|                            | 50.6              | 44.7                     |
|                            | 62.8              | 61.6                     |
| Pill                       | 6.8               | 9.0                      |
|                            | 4.6               | 4.5                      |
|                            | 9.8               | 17.5                     |
| Number of side effects     |                    |                          |
| None                       | 77.2              | 73.5                     |
|                            | 72.1              | 65.1                     |
|                            | 81.7              | 80.6                     |
| 1                          | 4.8               | 5.3                      |
|                            | 3.0               | 2.5                      |
|                            | 7.5               | 10.8                     |
| 2 or more                  | 18.0              | 21.2                     |
|                            | 13.8              | 14.2                     |
|                            | 23.0              | 30.4                     |
| Specific side effect       |                    |                          |
| Less bleeding              | 9.3               | 10.8                     |
|                            | 6.2               | 5.7                      |
|                            | 13.6              | 19.4                     |
| More bleeding              | 5.6               | 5.0                      |
|                            | 3.5               | 2.5                      |
|                            | 9.0               | 9.7                      |
| Irregular bleeding         | 7.3               | 6.8                      |
|                            | 4.4               | 3.5                      |
|                            | 11.9              | 12.9                     |
| Changes to sexual experience| 5.4               | 6.6                      |
|                            | 3.1               | 3.0                      |
|                            | 9.2               | 13.8                     |
| Physical discomfort        | 13.1              | 15.4                     |
|                            | 9.2               | 10.5                     |
|                            | 18.4              | 22.0                     |
Table 7  Complete list of potential side-effect answer choices included in survey

| Less bleeding          |
|------------------------|
| More bleeding          |
| Irregular bleeding     |
| Spotting               |
| Uterine cramping       |
| More cramping          |
| Weight gain            |
| Weight loss            |
| Facial spotting        |
| Headache               |
| Infection              |
| Nausea                 |
| Lowered libido         |
| Vaginal dryness        |
| Weakness               |
| Diarrhea               |
| Delayed return to fertility |
| Infertility            |
| Method lost inside body |
| Other                  |

Abbreviations
PMA2020: Performance Monitoring and Accountability 2020; PMA: Performance Monitoring for Action; DHS: Demographic and Health Survey; MICS: Multiple Indicator Cluster Survey; LMICS: Low- and middle-income countries; TFR: Total fertility rate; EA: Enumeration area; IUD: Intrauterine device; OR: Odds ratio.

Acknowledgements
The authors thank Caroline Moreau for helpful comments and suggestions and Amy Tsui for supervision and oversight.

Authors’ contributions
LZ conceptualized the research question, led analysis, and was responsible for drafting the manuscript. DS assisted in all stages of conceptualization, analysis, and writing. CK and SW were major contributors to interpretation of results, and substantive edits to the manuscript. FM and SK led study implementation, provided interpretation of results, and substantive edits to the manuscript. All authors read and approved the final manuscript.

Funding
This research was funded by the Bill and Melinda Gates Foundation (Grant INV-010478). The funders had no role in the design of the study, collection, analysis, interpretation of data, or in writing the manuscript.

Availability of data and materials
The datasets supporting the conclusions of this article are available at www.pmadata.org. All data are available upon request.

Declarations
Ethics approval and consent to participate
All data collection procedures were approved by Institutional Review Boards (IRBs) at the Makerere University School of Public Health and Uganda National Council of Sciences and Technology in Kampala, Uganda, and the Johns Hopkins Bloomberg School of Public Health in Baltimore, USA. After eligibility was confirmed, women were asked to complete written consent; if the woman agreed to participate, she was then interviewed by a trained resident interviewer. For unmarried women aged 15–17, written consent was first obtained from a parent or legal guardian prior to the women providing written assent to participate.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Author details
1 Department of Population, Family and Reproductive Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, USA. 2 Department of Epidemiology and Biostatistics, School of Public Health, Makerere University, Kampala, Uganda. 3 Department of Community Health and Behavioural Sciences, School of Public Health, Makerere University, Kampala, Uganda.

Received: 21 July 2020  Accepted: 6 November 2021
Published online: 27 November 2021

References
1. Castle S, Askew I. Contraceptive discontinuation: reasons, challenges, and solutions. Washington, DC: Population Council and FP2020, 2015. p. 41.
2. Bradley SEK, Schwandt HM, Khan S. Levels, trends, and reasons for contraceptive discontinuation. Calverton: ICF Macro, 200AD. (DHS Analytical Studies). Report No.: 20. https://www.dhsprogram.com/pubs/pdf/AS20/AS20.pdf. Accessed 5 Mar 2021.
3. Westhoff CL, Heartwell S, Edwards S, Zieman M, Stuart G, Cwiak C, et al. Oral contraceptive discontinuation: do side effects matter? Am J Obstet Gynecol. 2007;196(4):412.e1-412.e7.
4. Rosenberg MJ, Waugh MS. Oral contraceptive discontinuation: a prospective evaluation of frequency and reasons. Am J Obstet Gynecol. 1998;179(3 Pt 1):577–82.
5. Diamond-Smith N, Campbell M, Madan S. Misinformation and fear of side-effects of family planning. Cult Health Sex. 2012;14(4):421–33.
6. Schwartz J, Dumbaugh M, Bapolisi W, Ndorere MS, Mwamini M-C, Bisimwa G, et al. “So that’s why I’m scared of these methods”: locating contraceptive side effects in embodied life circumstances in Burundi and eastern Democratic Republic of the Congo. Soc Sci Med. 2019;220:264–72.
7. Bawah AA, Akwoengo P, Simmons R, Phillips JF. Women’s fears and men’s anxieties: the impact of family planning on gender relations in Northern Ghana. Stud Fam Plann. 1999;30(1):54–66.
8. Campbell M, Sahin-Hodoglugil NN, Potts M. Barriers to fertility regulation: a review of the literature. Stud Fam Plann. 2006;37(2):87–98.
9. Hyttel M, Rasanathan JJK, Tellier M, Taremwa W. Use of injectable hormonal contraceptives: diverging perspectives of women and men, service providers and policymakers in Uganda. Reprod Health Matters. 2012;20(40):148–57.
10. Jain A, Reichenbach L, Ehsan I, Rob U. “Side effects affected my daily activities a lot”: a qualitative exploration of the impact of contraceptive side effects in Bangladesh. Open Access J Contracept. 2017;8:645–52.
11. Darroch JE, Sedgh G, Ball H. Contraceptive technologies: responding to women’s needs. New York: Guttmacher Institute, 2011. p. 52.
12. Kibira SPS, Muhumuza C, Bukeya JN, Atuyambe LM. “I Spent a Full Month Bleeding, I Thought I Was Going to Die…” a qualitative study of experiences of women using modern contraception in Wakiso District, Uganda. PLoS ONE. 2015;10(11):e0141998.
13. Uganda Bureau of Statistics (UBOS), ICF. Uganda Demographic and Health Survey 2016. Kampala: UBOS and ICF; 2016. p. 52.
14. Makerere University, School of Public Health at the College of Health Sciences, Bill and Melinda Gates Institute for Population and Reproductive Health at the Johns Hopkins Bloomberg School of Public Health. Performance Monitoring and Accountability 2020 (PMA2020) Survey Round 6, PMA2018/Uganda-R6. Uganda and Baltimore, Maryland, USA, 2018.
15. Polis CB, Hussain R, Berry A. There might be blood: a scoping review on women’s responses to contraceptive-induced menstrual bleeding.
changes. Reprod Health. 2018;15(1):114. https://doi.org/10.1186/s12978-018-0561-0.

16. Wood SN, Karp C, Zimmerman L. Women's sexual experiences as a side effect of contraception in low- and middle-income countries: evidence from a systematic scoping review. Sex Reprod Health Matters. 2020;28(1):1763552.

17. Odwe G, Obare F, Machiyama K, Cleland J. Which contraceptive side effects matter most? Evidence from current and past users of injectables and implants in Western Kenya. Contracept X. 2020;2:100030.

18. Geoginc DK, Balci O, Karatayli R, Colakoglu MC. Contraceptive efficacy and side effects of Implanon®. Eur J Contracept Reprod Health Care. 2007;12(4):362–5.

19. Reid RL, Fortier MP, Smith L, Mirkin S, Grubb GS, Constantine GD. Safety and bleeding profile of continuous levonorgestrel 90 mcg/ethinyl estradiol 20 mcg based on 2 years of clinical trial data in Canada. Contraception. 2010;82(6):497–502.

20. Harper CC, Rocco CH, Darney PD, von Hertaen H, Raine TR. Tolerability of levonorgestrel emergency contraception in adolescents. Am J Obstet Gynecol. 2004;191(4):1158–63.

21. Cristobal I, Lete LI, de la Vuda E, Perulo N, Arbat A, Canals I. One year quality of life measured with SEC-Qol in levonorgestrel 52 mg IUS users. Contraception. 2016;93(4):367–71.

22. Wong RC, Bell RJ, Thunuguntla K, McNamee K, Vollenhoven B. Implanon and the side effects discontinue their contraceptive method: insights from a combined oral contraceptive pill on continuation rates at 1 year. Contraception. 2013;88(4):523–31.

23. Capurchande R, Coene G, Schockaert I, Macia M, Meulemans H. “It is challenging… oh, nobody likes it!”: a qualitative study exploring Mozambican adolescents and young adults’ experiences with contraception. BMC Womens Health. 2016;16:48.

24. Abdel-Tawab N, Rama Rao D. Do improvements in client-provider interaction increase contraceptive continuation? Unraveling the puzzle. Patient Educ Couns. 2010;81(1):381–7.

25. Jain A, Dwyer SC, Mozumdar A, Tobey E. Not all women who experience side effects discontinue their contraceptive method: insights from a longitudinal study in India. Stud Fam Plann. 2021;52(2):165–78.

26. Ali MM, Cleland J, Shah IH. Causes and consequences of contraceptive discontinuation evidence from 60 demographic and health surveys. World Health Organization; 2012. https://www.who.int/reproductivehealth/publications/family_planning/9789241504058/en/.

27. Morse JE, Rowen TS, Steinauer J, Byamugisha J, Kakaire O. A qualitative assessment of Ugandan women’s perceptions and knowledge of contraception. Int J Gynecol Obstet. 2014;124(1):30–3.

28. Callahan RL, Brunie A, Mackenzie ACL, Wayack-Pambé M, Guieila G, Kibira SP, et al. Potential user interest in new long-acting contraceptives: results from a mixed methods study in Burkina Faso and Uganda. PLoS ONE. 2019;14(5):e021733.

29. Boosey R, Prestwich G, Deave T. Menstrual hygiene management amongst schoolgirls in the Rukungiri district of Uganda and the impact on their education: a cross-sectional study. Pan Afr Med J. 2014;19:253.

30. Hennegan J, Nansubuga A, Smith C, Redshaw M, Akullo A, Schwab KJ. Measuring menstrual hygiene experience: development and validation of the Menstrual Practice Needs Scale (MPNS-36) in Serors, Uganda. BMJ Open. 2020;10(2):e034461.

31. Miro G, Rutakumwa R, Nakiyangi-Miro J, Nakuya K, Musoke S, Namakula J, et al. Menstrual health and school absenteeism among adolescent girls in Uganda (MENISCUS): a feasibility study. BMC Women's Health. 2018;18(1):4.

32. Hennegan J, Shannon AK, Rubli J, Schwab KJ, Melendez-Torres GJ. Women’s and girls’ experiences of menstruation in low- and middle-income countries: a systematic review and qualitative metasynthesis. PLoS Med. 2019;16(5):e1002803.

33. Sedlander E, Bingenheimer JB, Thiongo M, Gichangi P, Rimal RN, Edberg M, et al. “They Destroy the Reproductive System”: exploring the belief that modern contraceptive use causes infertility. Stud Fam Plann. 2018;49(4):345–65.

34. Gueye A, Speizer IS, Corroon M, Okogbo CC. Belief in family planning myths at the individual and community levels and modern contraceptive use in urban Africa. Int Perspect Sex Reprod Health. 2015;41(4):191–9.

35. Dumbaugh M, Bapoli W, Bismwa G, Mlwamini M-C, Mommers P, Merten S. Navigating fertility, reproduction and modern contraception in the fragile context of South Kivu, Democratic Republic of Congo: “Les enfants sont une richesse” Cult Health Sex. 2019;21(3):327–37.

36. von Elm E, Altman D, Egger M, Pocock S, Gotzsche P, Vandebroucke J. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies.

37. Morse JE, Rowen TS, Steinauer J, Byamugisha J, Kakaire O. A qualitative assessment of Ugandan women’s perceptions and knowledge of contraception. Int J Gynecol Obstet. 2014;124(1):30–3.

Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

Learn more biomedcentral.com/submissions